Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients  by Chertow, Glenn M. et al.
Kidney International, Vol. 68 (2005), pp. 2794–2800
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Prealbumin, mortality, and cause-specific hospitalization in
hemodialysis patients
GLENN M. CHERTOW, D. JORDI GOLDSTEIN-FUCHS, J. MICHAEL LAZARUS, and GEORGE A. KAYSEN
Division of Nephrology, Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San
Francisco, California; Fresenius Medical Care North America, Lexington, Massachusetts; and Division of Nephrology, Departments
of Medicine and Biochemistry, University of California Davis, Davis, California
Prealbumin, mortality, and cause-specific hospitalization in
hemodialysis patients.
Background. Prealbumin (transthyretin) is a hepatic secre-
tory protein thought to be important in the evaluation of nu-
tritional deficiency and nutrition support. Prior studies have
suggested that the serum prealbumin concentration is inde-
pendently associated with mortality in hemodialysis patients,
even with adjustment for serum albumin and other nutritional
parameters.
Methods. To determine whether prealbumin was indepen-
dently associated with mortality and morbidity (cause-specific
hospitalization) in hemodialysis patients, we analyzed data on
7815 hemodialysis patients with at least one determination of
serum prealbumin during the last three months of 1997. Unad-
justed, case mix-adjusted, and multivariable-adjusted relative
risks of death were calculated for categories of serum preal-
bumin using proportional hazards regression. We also deter-
mined whether the prealbumin concentration was associated
with all-cause, cardiovascular, infection-related, and vascular
access–related hospitalization.
Results. The relative risk (RR) of death was inversely related
to the serum prealbumin concentration. Relative to prealbumin
≥40 mg/dL, the adjusted RRs of death were 2.41, 1.85, 1.49, and
1.23 for prealbumin <15, 15–20, 20–25, and 25–30 mg/dL, re-
spectively. The adjusted RRs of hospitalization due to infection
were 2.97, 1.95, 1.81, and 1.61 for prealbumin <15, 15–20, 20–
25, and 25–30 mg/dL, respectively. The adjusted RRs of vascular
access-related hospitalization were 0.48, 0.52, 0.58, and 0.71 for
prealbumin <15, 15–20, 20–25, and 25–30 mg/dL, respectively.
While serum albumin was strongly associated with mortality
and all-cause hospitalization, it was not associated with hos-
pitalization due to infection, and lower levels were associated
with higher rather than lower rates of vascular access–related
hospitalization.
Conclusion. In hemodialysis patients, lower prealbumin con-
centrations were associated with mortality and hospitalization
due to infection, independent of serum albumin and other clin-
ical characteristics. Higher prealbumin concentrations were as-
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sociated with vascular access–related hospitalization. In light of
these findings, more intensive study into the determinants and
biological actions of prealbumin (transthyretin) in end-stage
renal disease is warranted.
Protein energy malnutrition (PEM) affects a large frac-
tion of maintenance hemodialysis patients and is un-
equivocally associated with mortality and morbidity [1].
While difficult to define, PEM depends on several in-
tersecting dimensions of health and disease, including
reduced dietary intake, sarcopenia, and loss of subcuta-
neous fat (often referred to as “somatic mass”) and re-
duced concentrations of plasma proteins and leukocytes
(often referred to as “visceral mass”) [2]. Inflammation
directly affects the catabolism of plasma proteins as well
as hepatic synthesis [3].
While serum albumin has proved to be a potent predic-
tor of mortality and cardiovascular morbidity in patients
with end-stage renal disease (ESRD), several studies
have suggested that other plasma proteins, including pre-
albumin, have additive predictive value [4–9]. For exam-
ple, we previously demonstrated a significant (2.5-fold)
increase in risk among hemodialysis patients with pre-
albumin concentrations <20 mg/dL, but were unable to
identify an optimal prealbumin concentration, or a level
below which a definitive increase in risk could be iden-
tified [10]. Moreover, prior studies have focused only
on mortality without consideration of hospitalization or
other morbidities.
Therefore, we aimed to determine the risk profile as-
sociated with the spectrum of prealbumin concentra-
tions in a large cohort of hemodialysis patients, using
mortality as the principle outcome of interest. We also
explored the association between prealbumin concentra-
tion and cause-specific hospitalization. We hypothesized
that prealbumin would be independently associated with
mortality and associated with hospitalization due to car-
diovascular disease and infection.
2794
Chertow et al: Prealbum, mortality, and cause-specific hospitalization in HD patients 2795
METHODS
Data source
The sample of patients was taken from the Fresenius
Medical Care North America Patient Statistical Profile
system. The database and methods of abstraction have
been previously described [11]. The cohort consisted of
patients on thrice weekly hemodialysis as of January
1, 1998 who had at least one determination of serum
phosphorus and calcium during the last three months
of 1997. Where repeated, all laboratory data were aver-
aged to provide a better estimate of exposure. The sam-
ple included 40,538 patients. Of the 40,538 patients, 7815
(19.3%) had at least one serum prealbumin concentration
during the three-month period. Patients with and with-
out prealbumin determinations were compared to assess
generalizability. Prealbumin was categorized a priori into
seven categories in 5 mg/dL increments: <15, 15–20, 20–
25, 25–30, 30–35, 35–40, and ≥40 mg/dL.
The primary ICD-9-CM code for each hospitaliza-
tion was recorded. Cardiovascular hospitalization in-
corporated the following ICD-9-CM codes: 390−459
(diseases of the circulatory system), 518.4 (acute pul-
monary edema), 276.6 (fluid overload), 785 (symptoms
involving cardiovascular system), 786.5 (chest pain),
780.2 (syncope and collapse), and 798 (sudden death).
Infection-related hospitalization included the following
ICD-9-CM codes: 001−139 (infectious and parasitic dis-
eases), 320−324 (meningitis and encephalitis), 421 (en-
docarditis), 480−486 (pneumonia), 590 (infections of the
kidney), 680−686 (infections of the skin and subcuta-
neous tissue), and 790.7 (bacteremia). Vascular access–
related (non-infection–related) hospitalization included
ICD-9-CM codes 996.1 and 996.70, 73, and 74.
Several confounding variables were included in the
analyses. Age, sex, race, or ethnicity, diabetes, and vin-
tage (time since initiation of dialysis) were considered to
represent “case mix.” Laboratory variables included pa-
rameters of mineral metabolism [phosphorus, calcium,
and parathyroid hormone (PTH)], hematologic status
(hemoglobin and ferritin), and other markers of nutri-
tional status [serum albumin, predialysis blood urea ni-
trogen (BUN), creatinine, cholesterol, and bicarbonate].
Body size was estimated using body weight, body surface
area, or Quete`let’s (body mass) index. Dialysis dose was
estimated using the urea reduction ratio (URR) or the
indexed or nonindexed urea clearance × time product
(Kt/Vurea and Kturea).
Statistical analyses
Continuous variables were expressed as mean ± stan-
dard deviation or median with interquartile range and
compared with parametric [Student t test or analysis of
variance (ANOVA)] or nonparametric tests (Wilcoxon
rank sum test or the Kruskal–Wallis test), where ap-
propriate. Categorical variables were expressed as pro-
portions and compared with the v 2 test. We calculated
unadjusted survival rates using the Kaplan–Meier prod-
uct limit method. Unadjusted, case mix–adjusted, and
multivariable-adjusted survival analyses were performed
using the proportional hazards regression model. Rela-
tive risks (RR) and 95% confidence intervals (95% CI)
were calculated from model parameter coefficients and
standard errors, respectively. Multivariable models were
constructed with backward variable selection, using P <
0.05 for variable retention. Plots of log (−log [survival
rate]) against log (survival time) were performed to estab-
lish the validity of the proportionality assumption. Effect
modification was evaluated by including multiplicative
interaction terms for selected variables. Factors not in-
cluded in multivariable models were reentered individu-
ally to evaluate for residual confounding (>10% change
in the parameter estimate for prealbumin or albumin).
There were few missing laboratory data except for PTH
(N = 1566, 20%) and cholesterol (N = 1946, 25%). To
avoid a significant loss of power we categorized these
data and included missing indicator variables in regres-
sion models. Patients who underwent kidney transplanta-
tion (N = 337, 4.3%), recovered kidney function (N = 34,
0.4%), transferred dialysis facilities (N = 1071, 13.7%),
withdrew from dialysis (N = 303, 3.9%), or were lost to
follow-up for unknown reasons (N = 4, 0.05%) were cen-
sored. Two-tailed P-values < 0.05 were considered sta-
tistically significant. Statistical analyses were conducted
using SAS 8.2 (SAS Institute, Cary, NC, USA).
RESULTS
Clinical characteristics of patients with and
without prealbumin determinations
To determine whether there were material differences
in patients who did and did not have determinations
of serum prealbumin during the evaluation period, we
compared baseline characteristics of the two populations
(N = 7815 and N = 32,723, respectively, shown in Table 1).
Many of the differences were relatively small, although
statistically significant, owing to the large sample sizes.
Patients who were tested were less likely to be African
American (34.3% vs. 45.1%, P < 0.0001). The mean age
was only slightly higher in tested patients. Testing was
unrelated to sex or diabetes. Among tested patients, the
median vintage was lower; body weight, Quete`let’s index,
serum creatinine, and albumin were significantly lower,
although modestly so.
The difference in the fraction of African Americans
among tested and nontested patients confounded the
differences in baseline nutritional indicators. For exam-
ple, among African Americans, testing was unrelated to
the mean serum albumin concentration (P = 0.33), and
patients who were tested had marginally higher serum
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Table 1. Clinical characteristics of patients with and without
prealbumin determinations
+Prealbumin −Prealbumin
(N = 7815) (N = 32,723) P value
Age years 61.5 ± 15.1 60.3 ± 15.1 <0.0001
Sex% female 51.0% 51.3% 0.61
Race/ethnicity% <0.0001
Caucasian 46.2% 35.3%
African American 34.3% 45.1%
Hispanic 16.4% 16.0%
Other 3.2% 3.6%
Diabetes% 46.5% 46.5% 0.93
Vintage years 1.61 (0.76–2.80) 1.72 (0.77–3.00) <0.0001
Weight kg 71.5 ± 18.1 72.4 ± 18.7 <0.0001
Quete`let’s (body mass) 26.4 ± 7.4 26.7 ± 7.8 0.0012
index kg/m2
Bicarbonate mEq/L 20.6 ± 3.0 21.1 ± 3.0 <0.0001
BUN mg/dL 59.1 ± 16.6 59.0 ± 16.5 0.54
Creatinine mg/dL 9.3 ± 3.3 9.7 ± 3.3 <0.0001
Albumin g/dL 3.84 ± 0.40 3.86 ± 0.40 <0.0001
Cholesterol mg/dL 169 ± 42 171 ± 42 0.0005
Hemoglobin g/dL 10.5 ± 1.1 10.4 ± 1.1 0.002
Ferritin lg/L 406 (202–675) 415 (209–686) 0.0001
URR% 68.4% ± 7.6% 68.7% ± 7.3% 0.0004
Phosphorus mg/dL 5.8 ± 1.6 5.8 ± 1.6 0.51
Calcium mg/dL 9.1 ± 0.8 9.0 ± 0.8 0.0005
PTH pg/mL 132 (60–295) 153 (68–348) <0.0001
Note: mean ± standard deviation except for vintage, ferritin, and PTH (me-
dian, interquartile range).
creatinine concentrations than those not tested (11.0 ±
3.5 vs. 10.8 ± 3.4, P = 0.04).
Crude mortality rates were higher in the tested popu-
lation (22.5% vs. 19.8% in the nontested population, P <
0.0001). However, after adjusting for baseline covariates,
the risk associated with prealbumin testing was atten-
uated and race-dependent. Among African Americans,
testing for prealbumin was significantly associated with
mortality (RR 1.17, 95% CI 1.08 to 1.29), whereas among
non-African Americans, the association between preal-
bumin testing and mortality was weak (RR 1.06, 95% CI
0.99 to 1.12). Thus, the cohort with prealbumin data ap-
peared to be somewhat sicker than the general hemodial-
ysis population.
Distribution and correlates of prealbumin
The mean serum prealbumin was 32.0 ± 8.8 mg/dL.
The mean serum prealbumin was significantly higher with
younger age, and significantly higher in men (32.9 vs.
31.1 mg/dL in women, P < 0.0001), African Americans
(33.9 vs. 30.9 in whites, P < 0.0001), and among persons
without diabetes (33.3 vs. 30.5 mg/dL in persons with
diabetes, P < 0.0001). Table 2 shows the distribution
of patient characteristics by categories of prealbumin
concentration. Serum prealbumin concentrations were
directly related to other parameters of nutritional sta-
tus, including body weight and laboratory proxies of
nutritional status and dietary intake (i.e., predialysis
blood urea nitrogen, creatinine, albumin, phosphorus,
and bicarbonate).
Prealbumin and mortality
Figure 1 shows the relative risks (RR) of mortality asso-
ciated with prealbumin concentration, considering serum
prealbumin ≥40 mg/dL as the referent category. The un-
adjusted results showed significantly increased RRs (95%
CI) for all categories of prealbumin below 40 mg/dL: 6.72
(5.35 to 8.48), 4.12 (3.44 to 4.94), 2.82 (2.39 to 3.23), 2.04
(1.73 to 2.40), 1.58 (1.38 to 1.86), and 1.37 (1.15 to 1.63)
for prealbumin <15, 15–20, 20–25, 25–30, 30–35, and 35–
40 mg/dL, respectively. The RRs were attenuated with
adjustment for case mix, although all categories of preal-
bumin retained a significantly higher RR than the refer-
ent category. On multivariable analysis, including serum
albumin and other nutritional parameters, the adjusted
RRs were 2.41 (1.84 to 3.16), 1.85 (1.50 to 2.27), 1.49
(1.24 to 1.78), and 1.23 (1.04 to 1.47), for prealbumin cat-
egories of <15, 15–20, 20–25, and 25–30 mg/dL, respec-
tively. The RR associated with prealbumin 30–35 mg/dL
was increased by 16%, but not significantly so. Other pre-
dictors of mortality included: advanced age, male sex,
white race, diabetes, longer dialysis vintage, lower body
weight, hemoglobin, and serum albumin and creatinine,
and higher phosphorus, calcium, and PTH (Table 3).
There were U- or J-shaped relations among mortality and
bicarbonate, ferritin, and URR.
Prealbumin, albumin, and hospitalization
There were 4805 hospitalizations recorded. Lower
prealbumin concentrations were associated with an in-
creased risk of all-cause hospitalization. The RRs were
1.95 (1.60 to 2.37), 1.67 (1.48 to 1.89), 1.55 (1.40 to 1.72),
1.30 (1.18 to 1.42), and 1.17 (1.07 to 1.28) for prealbu-
min <15, 15–20, 20–25, 25–30, and 30–35, respectively.
As above, the RRs of all-cause hospitalization were at-
tenuated with adjustment for case mix, although RRs
for all categories of prealbumin remained significantly
higher than the referent category. The multivariable RRs
of all-cause hospitalization were 1.58 (1.29 to 1.93), 1.37
(1.20 to 1.56), 1.32 (1.18 to 1.47), and 1.15 (1.04 to 1.27),
for prealbumin categories of <15, 15–20, 20–25, and 25–
30 mg/dL, respectively. Other predictors of all-cause hos-
pitalization were older age, white race, diabetes, lower
body weight, lower hemoglobin, bicarbonate, and URR
and higher ferritin.
Cardiovascular hospitalization
There were 1180 cardiovascular hospitalizations
recorded. The association between prealbumin con-
centration and cardiovascular hospitalization was of
marginal statistical significance (RR 1.08, 95% CI 1.01 to
1.15 per 10 mg/dL decrease), and was not significant after
multivariable adjustment (RR 1.07, 95% CI 0.99 to 1.15).
Other predictors of cardiovascular hospitalization were
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Table 2. Clinical characteristics by prealbumin concentration
<15 15–20 20–25 25–30 30–35 35–40 ≥ 40
(N = 170) (N = 524) (N = 1022) (N = 1512) (N = 1736) (N = 1411) (N = 1440) P value
Age years 64.8 66.1 63.8 63.6 61.1 60.6 56.8 <0.0001
Sex% female 53.5% 56.9% 54.2% 51.7% 50.8% 47.3% 38.6% <0.0001
Race/ethnicity%
Caucasian 50.6% 53.2% 49.5% 53.0% 47.1% 42.4% 36.1%
African American 29.4% 25.6% 27.5% 27.1% 33.2% 39.3% 46.9%
Hispanic 18.2% 18.1% 19.6% 17.2% 16.8% 14.3% 13.8%
Other 1.8% 3.1% 3.4% 2.8% 2.9% 4.0% 3.3%
Diabetes% 55.3% 56.9% 58.4% 51.4% 45.6% 43.4% 32.5% <0.0001
Vintage years 1.37 1.27 1.38 1.62 1.63 1.65 1.69 <0.0001
Weight kg 67.9 67.5 68.0 70.2 71.8 73.2 75.3 <0.0001
Quete`let’s index kg/m2 25.4 25.2 25.4 26.2 26.5 27.0 27.2 <0.0001
Bicarbonate mEq/L 21.5 21.6 21.0 20.9 20.6 20.3 19.9 <0.0001
BUN mg/dL 44.3 49.6 53.7 56.3 60.0 62.7 66.4 <0.0001
Creatinine mg/dL 6.3 7.0 7.9 8.5 9.4 10.2 11.5 <0.0001
Albumin g/dL 3.12 3.41 3.62 3.78 3.88 3.98 4.11 <0.0001
Cholesterol mg/dL 124 142 155 167 173 179 186 <0.0001
Hemoglobin g/dL 9.8 10.0 10.2 10.4 10.6 10.6 10.7 <0.0001
Ferritin lg/L 406 370 388 381 391 415 432 <0.0001
URR% 66.2% 67.6% 67.7% 68.8% 68.5% 68.8% 68.3% 0.002
Phosphorus mg/dL 5.1 5.3 5.6 5.7 5.9 5.9 6.0 <0.0001
Calcium mg/dL 8.6 8.8 8.9 9.0 9.1 9.2 9.3 <0.0001
PTH pg/mL 106 126 124 125 132 143 149 0.0005
Note: mean ± standard deviation except for vintage, ferritin, and PTH (median, interquartile range).
Fig. 1. The relative risk of death associ-
ated with serum prealbumin concentration.
Light gray bars are unadjusted. Medium gray
bars are case mix-adjusted (age, sex, race
or ethnicity, diabetes, and vintage). Black
bars are multivariable-adjusted (case mix +
body weight, dialysis dose, and serum concen-
trations of creatinine, albumin, bicarbonate,
hemoglobin, ferritin, phosphorus, calcium,
and PTH).
advanced age, diabetes, higher concentrations of phos-
phorus, calcium, and ferritin, and lower concentrations
of bicarbonate. The serum albumin was not associated
with cardiovascular hospitalization in this cohort (P =
0.70).
Infection-related hospitalization
There were 567 hospitalizations attributed to infection.
Lower prealbumin concentrations were associated with
an increased risk of hospitalization due to infection. Ad-
justed RRs were 2.97 (1.88 to 4.70), 1.95 (1.36 to 2.80),
1.81 (1.33 to 2.47), and 1.61 (1.20 to 2.16) for prealbu-
min <15, 15–20, 20–25, and 25–30 mg/dL, respectively.
The RR associated with prealbumin 30–35 mg/dL was
increased by 24%, but not significantly so. Of the 567
hospitalizations due to infection, 234 (41%) were associ-
ated with pneumonia and 141 (25%) separately coded for
bacteremia or sepsis. There was no association between
serum albumin (and other laboratory variables) and the
risk of hospitalization due to infection.
Vascular access–related hospitalization
Finally, we examined the associations among pre-
albumin, albumin, and vascular access–related (non-
infection–related) hospitalization (N = 696). Lower
prealbumin concentrations were associated with a
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Table 3. Prealbumin and other predictors of mortality on
multivariable analysis
Factor RR 95% CI P-value
Prealbumin referent 40 mg/dL
<15 mg/dL 2.41 1.84 to 3.16 <0.0001
15–20 mg/dL 1.85 1.50 to 2.27 <0.0001
20–25 mg/dL 1.49 1.24 to 1.78 <0.0001
25–30 mg/dL 1.23 1.04 to 1.47 0.017
30–35 mg/dL 1.16 0.98 to 1.37 0.09
35–40 mg/dL 1.08 0.90 to 1.29 0.40
Age per decade 1.28 1.24 to 1.33 <0.0001
Male referent female 1.26 1.14 to 1.38 <0.0001
Race or ethnicity referent white
African American 0.90 0.80 to 1.00 0.06
Hispanic 0.83 0.73 to 0.94 0.003
Other 0.75 0.57 to 1.00 0.047
Diabetes referent no diabetes 1.21 1.11 to 1.33 <0.0001
Vintage referent <2 years
2–5 years 1.17 1.04 to 1.31 0.008
≥5 years 1.27 1.07 to 1.52 0.007
Body weight per 10 kg 0.91 0.89 to 0.94 <0.0001
Creatinine per mg/dL 0.93 0.91 to 0.95 <0.0001
Albumin per 0.1 g/dL 0.94 0.93 to 0.96 <0.0001
Hemoglobin per g/dL 0.88 0.85 to 0.92 <0.0001
Calcium per mg/dL 1.17 1.10 to 1.24 <0.0001
Phosphorus per mg/dL 1.09 1.06 to 1.13 <0.0001
PTH per 100 pg/mL 1.01 1.00 to 1.03 0.03
In addition to the factors noted above, there were curvilinear associations
between URR and mortality (P = 0.004 and P = 0.0007) for linear and quadratic
terms, bicarbonate and mortality (P = 0.0007 and P = 0.003 for linear and
quadratic terms), and ferritin and mortality (P < 0.0001 and P = 0.0005 for linear
and quadratic terms).
decreased risk of vascular access–related hospitalization.
Adjusted RRs were 0.48 (0.25 to 0.90), 0.52 (0.35 to 0.77),
0.58 (0.43 to 0.78), 0.71 (0.55 to 0.92) for prealbumin <15,
15–20, 20–25, and 25–30 mg/dL, respectively. In contrast,
higher serum albumin was associated with a decrease in
the risk of access-related hospitalization (adjusted RR
0.72, 95% CI 0.58 to 0.90 per 1 g/dL increase).
Vintage, prealbumin, and mortality
In addition to the effects of dietary intake and inflam-
mation on prealbumin, the degree of kidney function may
influence prealbumin concentrations. To explore whether
residual kidney function was confounding the relations
among prealbumin and outcomes, we tested whether the
association between prealbumin and mortality was influ-
enced by vintage, a reasonable proxy for residual kidney
function. We also evaluated for effect modification by age,
sex, race, or ethnicity and diabetes. No interaction terms
were statistically significant (P > 0.20 for all interactions,
individually or in combination).
Prealbumin and albumin combinations
To determine the predictive power of serum prealbu-
min across the range of serum albumin concentrations,
we ranked both laboratory parameters into quintiles, and
examined the RR of mortality associated with serum pre-
albumin concentrations within relatively narrow, fixed
concentrations of albumin. The median within each pre-
albumin quintile was 20.7, 27.1, 31.9, 36.6, and 43.2 mg/dL.
The median within each albumin quintile was 3.33, 3.67,
3.87, 4.07, and 4.30 g/dL. Figure 2 shows the RR of mor-
tality for prealbumin quintiles within albumin quintiles.
Lower prealbumin concentrations were associated with
increased risk across the spectrum of serum albumin—
particularly among patients at the extremes.
DISCUSSION
Prealbumin, also known as transthyretin, is a 54,000 D
protein synthesized primarily by the liver. Its main func-
tion is to transport thyroxine and indirectly vitamin A, as
it serves as a carrier protein for retinol-binding protein
[12]. In humans, prealbumin has been shown to increase
with increases in protein and calorie intake and to de-
crease when protein intake is inadequate [12]. In addi-
tion, albumin and prealbumin are negative acute-phase
proteins. Serum concentrations of albumin and prealbu-
min decline in response to inflammation as a consequence
at least in part of decreased synthesis [13, 14], although
other factors such as altered vascular permeability af-
fect the concentrations of these plasma proteins [15]. In
contrast to serum albumin, the half-life of prealbumin is
relatively short (approximately 2–3 days vs. 14–21 days)
[16, 17]. It has therefore been suggested that prealbumin
may be a more sensitive indicator of nutritional status
than serum albumin [18, 19].
Several studies have demonstrated an association
between prealbumin and mortality [4–10]. For exam-
ple, Mittman et al [8] found that a serum prealbumin
<30 mg/dL at the initiation of dialysis was associated
with an increased risk of death in 258 dialysis patients
(half on peritoneal, half on hemodialysis) followed over
10 years, even with adjustment for age, sex, race or eth-
nicity, diabetes, vintage, and other nutritional parameters.
In an earlier report, prealbumin values <25 mg/dL were
associated with mortality in unadjusted and case mix–
adjusted analyses, but the multivariable results were sig-
nificant only with prealbumin concentrations <20 mg/dL
[10]. In the present study, we demonstrated a graded in-
crease in the mortality risk across the spectrum of pre-
albumin concentrations, with significant increases in risk
observable below 40 mg/dL (<30 mg/dL with multivari-
able adjustment), suggesting that optimal values are in
excess of 30–40 mg/dL.
As before, we demonstrated that while albumin and
prealbumin are directly correlated, both are strongly
and independently associated with mortality. The dis-
parate associations of albumin and prealbumin with
cause-specific hospitalization are of particular interest.
In this cohort, prealbumin concentration was associated
with the risk of hospitalization due to infection, while
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Fig. 2. The relative risk of death associated
with serum prealbumin (in quintiles), strati-
fied by quintiles of serum albumin (denoted
as Alb Q1, Q2, Q3, Q4, and Q5).
albumin concentration was not. Since prealbumin is a
negative acute-phase protein that is relatively short lived,
it may be a particularly sensitive reflection of activation of
the acute-phase response. Prior activation of the acute-
phase response has been associated with decreased re-
lease of interleukin-6 and tumor necrosis factor-alpha
when patients are subsequently challenged with an in-
fectious agent, potentially explaining the increased risk
of infection associated with low levels of prealbumin
[20]. Patients with evidence of activation of the acute-
phase response, as evidenced by increased concentrations
of C-reactive protein, interleukin-6, and a-1-antitrypsin
and decreased concentrations of prealbumin preopera-
tively experience a higher risk of postoperative infec-
tious complications [21, 22]. Moreover, decreased levels
of prealbumin and other negative acute-phase proteins
are associated with decreased cellular-mediated immu-
nity [23], abnormalities that may be reversed with par-
enteral nutrition [24].
Previous studies have demonstrated an association be-
tween hypoalbuminemia and vascular access thrombo-
sis [25, 26]. We were initially surprised to observe a
lower risk of vascular access–related hospitalizations with
lower prealbumin concentrations. We cannot determine
the mechanism underlying this association. Prealbumin
may be a more sensitive indicator of acute hepatic dys-
function than albumin [27]. In a small study of cancer
patients receiving cefoperazone, lower prealbumin con-
centrations were associated with hypoprothrombinemia
[28]. While laboratory proxies of the coagulation cascade
were not available on the 7815 patients described here,
there was a strong association between prealbumin and
cholesterol, another marker of the liver’s synthetic capac-
ity (Table 2). Moreover, median aspartate aminotrans-
ferase (AST) concentrations were significantly higher
among patients with low prealbumin concentrations, as
was the proportion of patients with AST above the labo-
ratory normal range (data not shown).
There are several limitations to the data presented
here. First, residual confounding might dampen or en-
hance the relative risks described here. More precise es-
timates of risk associated with prealbumin concentrations
might be obtained with additional adjustment for comor-
bidity and inflammatory markers, although these would
be unlikely to extinguish the associations described. Sec-
ond, because prealbumin concentrations were measured
at baseline, some exposures may have been misclassi-
fied. Had prealbumin been analyzed as a time-dependent
covariate, the magnitude of the relative risks would
have probably been higher. Third, the use of primary
ICD-9-CM diagnosis codes limits the capacity to iden-
tify associations between prealbumin and cause-specific
hospitalization. There may have been additional hospi-
talizations for infection or vascular access that were not
captured. In particular, the 270 (5.5%) hospitalizations
coded with the primary ICD-9-CM code 585 (chronic
renal failure) may have had informative secondary and
tertiary ICD-9-CM codes. Finally, the study sample was
restricted to hemodialysis patients, so that the associa-
tions described cannot be extrapolated to peritoneal dial-
ysis patients or to persons with less severe degrees of
chronic kidney disease.
CONCLUSION
In a cohort of 7815 hemodialysis patients, lower pre-
albumin concentrations were associated with mortality,
all-cause hospitalization and, particularly, hospitaliza-
tion for infection. These findings were independent of
age, sex, race, diabetes, vintage, and other laboratory
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factors, including serum albumin. Serum prealbumin
concentrations >30–40 mg/dL were associated with the
lowest risk of death. These data support the presence of
unique pathophysiologic pathways within which prealbu-
min may operate, and suggest that monitoring of prealbu-
min should be incorporated into nutritional assessment
and monitoring in dialysis units. Additional work is re-
quired to better understand the biological functions of
prealbumin and the specific response of the protein to
exogenous factors, such as uremia, starvation, and nutri-
tion intervention.
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